A proven antibiotic that works on the inside

Significantly decreases Staphylococcus aureus (S aureus) eyelid bacteria

Minocycline significantly decreased S aureus colony-forming units (CFU) from 59.9 at baseline
to 0.4 at 3 months (P=0.0139)¹

Study design: A total of 10 patients were enrolled in this prospective study, with 6 patients diagnosed with acne rosacea with concomitant meibomianitis,
2 patients with acne rosacea without concomitant ocular involvement, and 2 patients with seborrheic blepharitis. The eyelids and conjunctiva of both eyes were cultured before the initiation of systemic minocycline therapy, after 3 months of active therapy, and 3 months after the discontinuation of therapy.

Minocycline — an alternative treatment for blepharitis

Reduces the signs and symptoms associated with blepharitis²
One of the most frequently prescribed oral tetracyclines for ocular surface disorders³

Convenient dosing flexibility

Easy-to-swallow 50 mg coated tablets
Easily absorbed—foods (including dairy products) are not likely to interfere
with absorption, unlike with tetracycline⁴

Important Safety Information:
Cleeravue-M™ is indicated for the treatment of skin and skin structure infections caused by Staphylococcus aureus.
Cleeravue-M™ is contraindicated in persons with known hypersensitivity to any of the tetracyclines or to any of the product components. Minocycline, like other tetracycline-class antibiotics, can cause fetal harm when administered to a pregnant woman.
The use of drugs of the tetracycline class during tooth development (last half of pregnancy, infancy, and childhood to the age of 8 years) may cause permanent discoloration of teeth. Tetracycline drugs should not be used during tooth development unless other drugs are not likely to be effective or are contraindicated.
Patients should be advised that photosensitivity can occur with the tetracycline-class drugs. Side effects to the lower bowel, particularly diarrhea, have been infrequent. With renal impairment, even usual oral or parenteral tetracycline doses may lead to excessive systemic accumulations of the drug and possible liver toxicity. CNS side effects and systemic hypersensitivity reactions have been reported.

*Contains Cleeravue-M™ tablets plus SteriLid^® eyelid cleanser.

Click here for full Cleeravue-M™ Prescribing Information

References:

1. Ta CN, Shine WE, McCulley JP, Pandya A, Trattler W, Norbury JW. Effects of minocycline on the ocular flora of patients with acne rosacea or seborrheic blepharitis. Cornea. 2003;22(6):545-548. 2. Aronowicz JD, Shine WE, Oral D, Vargas JM, McCulley JP. Short-term oral minocycline treatment of meibomianitis. Br J Ophthalmol. 2006. Available at: http://bjo.bmjjournals.com/cgi/content/abstract/bjo.2006.091579v1. Accessed May 25, 2006. 3. IMS: National Prescription Audit, Therapeutic Category Report. 2006. 4. The Merck Manual. Tetracyclines. Available at: www.merck.com/mrkshard/mmanual/section13/chapter153/153e.jsp. Accessed June 6, 2006.